American Society of Hirudotherapy

Hip Osteoarthritis (Investigational Adjunct)

Investigational adjunct for symptomatic hip osteoarthritis; weight management, exercise, NSAIDs, and arthroplasty for end-stage disease remain evidence-based.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 12, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for hip osteoarthritis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational and lacks the RCT support that exists for knee OA.
What evidence exists?
Tier C (investigational). Randomized trials of leech therapy have been done in knee osteoarthritis, but no clinical study specific to hip OA was identified in PubMed or Europe PMC. The hip is a deep joint, and it is not known whether leech saliva can reach the joint capsule. Evidence-based first-line care per ACR / OARSI includes weight loss, supervised exercise therapy (land and aquatic), education and self-management, topical and oral NSAIDs, and intra-articular corticosteroid injection for short-term flare relief. Total hip arthroplasty has excellent durable outcomes for end-stage disease.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness over the hip and groin for 5 to 10 days
  • Risk to femoral neurovascular bundle if placement is improperly anterior to the inguinal ligament
  • Local skin infection or, rarely, Aeromonas infection
  • Allergic reaction to leech saliva (uncommon)
  • Temporary worsening of hip pain or stiffness for 1 to 3 days
  • Small bite marks that usually fade over weeks to months (rarely a pale spot stays longer)
  • Delay or replacement of hip arthroplasty in end-stage disease with progressive disability
Who should not consider this
  • Patients with end-stage hip OA where arthroplasty is indicated (outcomes are excellent and time-sensitive)
  • Patients with avascular necrosis of the femoral head
  • Patients with femoroacetabular impingement requiring surgical management
  • Patients with a hip prosthesis at or near the proposed application area
  • Patients with lumbar radiculopathy causing referred hip pain (workup first)
  • Patients on anticoagulants, with hemophilia, or with anemia
What to ask your clinician
  • Is my pain truly from hip OA, or could it be referred lumbar radiculopathy, sacroiliac joint, or trochanteric bursa?
  • What is my Kellgren-Lawrence grade, and what is my functional limitation?
  • Have I tried supervised exercise therapy and weight loss (if applicable) — the strongest non-surgical evidence?
  • Have I tried topical or oral NSAIDs, and considered an intra-articular corticosteroid injection?
  • Am I a candidate for hip arthroplasty? If yes, why am I considering complementary therapy?
  • Why would knee OA evidence apply to hip OA given the joint depth difference?
  • What is the practitioner's experience and Aeromonas-prevention plan?
When to seek urgent care
  • Sudden inability to bear weight, severe pain after a fall, or deformity (possible hip fracture — call 911)
  • New leg weakness, numbness, or loss of bladder / bowel control (cauda equina or radiculopathy)
  • Severe hot swollen joint with fever (possible septic arthritis)
  • Sudden severe leg pain, coldness, or pallor (possible vascular event)
  • Spreading redness, warmth, pus, or red streaks (cellulitis)
  • Bleeding from a bite site lasting more than 24 to 48 hours
  • Fever above 38.0 C / 100.4 F or chills
  • Hives, throat tightness, or breathing difficulty

What this does NOT mean

  • Knee OA evidence has not been shown to extend to hip OA; the hip joint is much deeper, and it is not known whether topical effects reach it.
  • It does not delay or replace hip replacement for end-stage disease; outcomes from arthroplasty are excellent and time-sensitive.
  • It does not address avascular necrosis or femoroacetabular impingement, which require surgical management.
  • No hip-specific clinical evidence was identified; any short-term relief may reflect placebo, attention, and natural fluctuation.

Clinical Profile

Category
Musculoskeletal
ICD-10
M16.0, M16.1, M16.10, M16.11, M16.12
Safety tier
Medium

Evidence Summary

Hip osteoarthritis (OA) is degenerative joint disease producing groin or anterior thigh pain and limited internal rotation. ACR/OARSI evidence-based first-line management includes weight loss, exercise therapy (land and aquatic), education and self-management, topical and oral NSAIDs, and intra-articular corticosteroid injection for short-term flare relief. End-stage disease responds to total hip arthroplasty with excellent durable outcomes. Randomized trials of leech therapy in knee OA (Michalsen 2003, Andereya 2008, Stange 2012) report symptom improvement, but no clinical study of hirudotherapy specific to hip OA was identified in PubMed, Europe PMC or ClinicalTrials.gov. The only clinical data that include hip OA are mixed-joint reports: Sulim (1998, cited in the Baskova and Isakhanyan 2004 monograph) described 162 patients with deforming arthrosis of the shoulder, wrist and knee joints and coxarthrosis, with pain resolved in 148; no control group or separate hip result is reported. Michalsen et al. 2007 add only practical remarks on treating the hip, not study results (see “What the books describe” below). The hip lies deep to the skin, and whether leech saliva can act on the joint is unknown. The deep femoral neurovascular bundle requires placement caution.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • Baskova and Isakhanyan mention coxarthrosis (arthrosis of the hip joint) only within a general group: they retell Sulim’s observations (1998) in 162 patients with deforming arthrosis of the shoulder, wrist and knee joints and with coxarthrosis; the results for the hip joint are not named separately[B1].
  • According to this description, leeches were used together with manual therapy and herbal medicine, and after treatment the pain disappeared in 148 patients (of these 162, as follows from the neighboring sentences); the description names no comparison group and no follow-up period[B1].
  • Michalsen et al. (chapter 5, Flecken and Michalsen) write that the hip joint, unlike the knee and shoulder joints, is poorly accessible to leech secretions because it is deeply embedded in muscle tissue, and that treating it is usually successful only in slim patients or when superficial muscles and tendons are heavily involved in the overall pain syndrome[B3].
  • In the chapter on the scientific basis (chapter 10), Michalsen calls the use of leeches in coxarthrosis possible but less promising, because the hip joint is poorly accessible to leeches, and writes that specific studies of efficacy in other forms of degenerative joint disease (from the context — apart from the knee) are currently lacking[B3].
  • Among the contraindications, Baskova and Isakhanyan name, for example, hemophilia, anemias and concurrent use of anticoagulants; Michalsen et al. (chapter 8, Flecken and Michalsen) likewise regard taking anticoagulants as an absolute contraindication, and do not regard aspirin and clopidogrel as contraindications in themselves — in that case, in their words, fewer leeches are applied at the first leech treatment session[B1][B3].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • End-stage OA where arthroplasty is indicated (refer to orthopedics)
  • Avascular necrosis of the femoral head
  • Femoroacetabular impingement requiring surgical management
  • Total hip arthroplasty in situ (placement over prosthesis area)
  • Lumbar radiculopathy with referred hip pain (workup first)

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.